Frontier Medicines
Frontier Medicines is a clinical-stage biopharmaceutical company developing covalent small-molecule precision medicines against previously undruggable cancer targets, using its proprietary chemoproteomics- and AI-powered Frontier™ Platform. It serves oncology patients via three pipeline programs and enterprise partners including AbbVie and LG Chem.
- Company typePrivate
- Founded2019
- HeadquartersSan Francisco, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Frontier Medicines does
Frontier Medicines is a clinical-stage biopharmaceutical company developing covalent small-molecule precision medicines against protein targets historically considered undruggable, with an initial focus on oncology. The company's core technology is the proprietary Frontier™ Platform, which integrates chemoproteomics, covalent chemistry, and artificial intelligence (CovalentAI™) to map more than 150,000 covalent binding sites across the human proteome and identify actionable ligands for over 8,000 targets. Built on a proprietary Covalent Ground Truth (CoGT™) dataset of more than 2 billion data points, the platform claims to advance clinical candidates in 1.5–2 years versus 3–5 years for conventional methods. Frontier's pipeline includes FMC-376, a dual ON+OFF KRAS G12C inhibitor in Phase 1/2 clinical trials (PROSPER trial); FMC-242, a covalent PI3Kα-RAS breaker in IND-enabling stage; and FMC-220, a covalent p53 Y220C activator licensed to LG Chem for development outside Greater China. The company also maintains a global strategic collaboration with AbbVie covering E3 ligases and certain oncology and immunology targets.
Frontier is headquartered in South San Francisco with a second research facility in Boston. It was founded in 2019 by Chris Varma, Ph.D. (former Blueprint Medicines CEO), Daniel K. Nomura, Ph.D., and Roberto Zoncu, Ph.D., both UC Berkeley faculty. The company has raised approximately $335.5 million in private funding across Series A ($67M, 2019), Series B ($88.5M, 2021), and Series C ($100M total, 2024) financing rounds from investors including Deerfield Management, Droia Ventures, MPM Capital, RA Capital Management, and Woodline Partners LP.
The business model is asset-light in commercial terms: Frontier generates revenue through pharmaceutical partnership upfronts, R&D reimbursements, milestone payments, and royalties rather than direct product sales, as no candidates are yet approved. The AbbVie partnership provides $55 million in upfront cash and eligibility for milestones exceeding $1 billion plus royalties; the LG Chem license for FMC-220 generates near-term development capital while Frontier retains Greater China commercial rights. Customers are exclusively enterprise pharmaceutical counterparties (AbbVie, LG Chem). End-user "customers" are oncology patients with KRAS-mutated, p53-mutated, and PI3Kα/RAS-pathway-altered cancers, though these are not direct purchasers.
Frontier Medicines firmographics
Firmographics- Name
- Frontier Medicines
- Legal name
- Frontier Medicines Corporation
- Website
- https://frontiermeds.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Frontier Medicines is a clinical-stage biopharmaceutical company developing covalent small-molecule precision medicines against previously undruggable cancer targets, using its proprietary chemoproteomics- and AI-powered Frontier™ Platform. It serves oncology patients via three pipeline programs and enterprise partners including AbbVie and LG Chem.
- Ownership category
- akta.pro rank
Frontier Medicines industry classification
Industry- Product category
- Precision Oncology Therapeutics
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industries
- Translational Medicine & Biomarkers (HLAIALAF), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
Keywords
Where Frontier Medicines is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Frontier Medicines business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Partnership and licensing revenue: Frontier Medicines generates revenue through strategic partnerships with pharmaceutical companies. They receive upfront payments, R&D reimbursements, milestone payments, and royalty payments on commercialized products. Example: AbbVie partnership with $55 million upfront, potential milestone payments exceeding $1 billion, plus royalties. LG Chem licensing deal for FMC-220 with development and commercialization rights.
- Drug development and commercialization: As a clinical-stage biopharmaceutical company, Frontier develops its proprietary pipeline of precision medicines through clinical trials with the goal of commercializing drugs. FMC-376 is in Phase 1/2 clinical trials (PROSPER trial). Revenue will be generated from future drug sales upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Frontier Medicines product offering
Product offeringCore offering
Frontier Medicines is a clinical-stage biopharmaceutical company that develops small molecule covalent drugs against previously undruggable disease-causing protein targets, primarily in oncology. Its proprietary Frontier Platform combines chemoproteomics, covalent chemistry, and artificial intelligence to discover covalent binding sites, identify actionable ligands, and accelerate optimization to clinical candidates. The company has a pipeline of precision oncology drug candidates including FMC-376 (KRAS G12C), FMC-220 (p53 Y220C), and FMC-242 (PI3Kα-RAS).
Product overview
Frontier Medicines is a precision medicine company developing a pipeline of small molecule drugs against previously undruggable cancer targets. The company's core offering is The Frontier™ Platform, a chemoproteomics and AI-powered covalent drug discovery system that enables identification of actionable binding sites across >90% of the human proteome. The platform comprises the Druggability Atlas™ (150,000+ covalent binding sites database), CovalentAI™ (AI-driven design engine), and an optimized covalent fragment library. The company's pipeline includes three named drug candidates: FMC-376 (dual KRAS G12C ON+OFF inhibitor in Phase 1/2 clinical trials), FMC-242 (PI3Kα-RAS breaker in IND-enabling stage), and FMC-220 (p53 Y220C activator licensed to LG Chem). The company also maintains a global partnership with AbbVie for E3 ligase and certain oncology/immunology targets.
Differentiator
Problem solved
Functional benefit
Brands
- The Frontier™ Platform: Proprietary platform powered by chemoproteomics, covalent chemistry, and artificial intelligence for drug discovery.
- Druggability Atlas™
- CovalentAI™
Products and services
- FMC-376 A first-in-class dual inhibitor targeting both ON (active) and OFF (inactive) states of KRAS G12C with exquisite selectivity, designed to overcome resistance seen with single-acting KRAS G12C treatments in NSCLC, colorectal carcinoma, and pancreatic cancer patients.
- FMC-220 A first-in-class covalent activator of p53 Y220C designed to selectively restore p53 tumor suppressor function for solid tumor cancers with TP53 Y220C mutations (including ovarian, lung, breast, colorectal cancers). Licensed to LG Chem for worldwide development and commercialization outside Greater China.
- FMC-242 A covalent allosteric inhibitor that breaks the PI3Kα-RAS interaction to inhibit downstream tumor signaling without impacting normal functions such as glucose homeostasis. Designed for lung, colorectal, and breast cancer patients as single agent or in combination with KRAS inhibitors.
Quantifiable outcome
- Access to over 90% of human proteins vs. less than 10% with traditional methods
- +5 more outcomes
Companies that use Frontier Medicines
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles1 record
Frontier Medicines technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Frontier Medicines partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and flagship.
- LG ChemcoreExclusive worldwide licensing agreement (outside of Greater China) for FMC-220, a first-in-class covalent p53 Y220C activator for solid tumor cancers. LG Chem leads regulatory, clinical, and commercial activities in their territories. Frontier retains full ownership within Greater China.
- AbbVieflagshipGlobal strategic collaboration to discover, develop and commercialize small molecule therapeutics against novel E3 ligases and certain oncology and immunology targets. AbbVie pays $55M upfront, reimburses R&D costs, and Frontier is eligible for milestones exceeding $1B plus royalties. AbbVie leads global development and commercialization; Frontier retains option to share development expenses for certain oncology programs through Phase 2.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Frontier Medicines competitors and assessment
Company assessmentDirect peers
- Revolution Medicines: Clinical-stage precision oncology company developing covalent inhibitors of difficult-to-drug targets including RAS(ON) inhibitors. Closest direct competitor to Frontier given overlapping focus on covalent chemistry against historically undruggable oncology targets, particularly in the RAS/MAPK pathway.
- Mirati Therapeutics: Developed Krazati (adagrasib), a KRAS G12C inhibitor competing directly with Frontier's FMC-376 in the same indication. Acquired by Bristol-Myers Squibb in 2024, Mirati represents the competitive benchmark Frontier's dual ON+OFF mechanism must beat in NSCLC, CRC, and other KRAS G12C-driven tumors.
- Black Diamond Therapeutics: Precision oncology company using its proprietary platform to discover small molecule kinase inhibitors against allosteric and mutant-specific targets. Compares to Frontier in its platform-driven approach to historically undruggable oncology targets and similar clinical-stage positioning.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology, chemistry, and machine learning at scale. Peer to Frontier's CovalentAI platform approach, though broader in modality and indication scope; both are technology-led discovery companies seeking to industrialize early-stage drug creation.
- Schrödinger Inc. Computational drug discovery platform combining physics-based simulation with machine learning to accelerate small molecule discovery. Comparable to Frontier as a platform-company leveraging computation/AI for early-stage drug discovery, though Schrödinger's platform is modality-agnostic vs. Frontier's covalent focus.
- Arvinas: Clinical-stage biotechnology company pioneering targeted protein degradation (PROTAC) using E3 ligase technology. Direct relevance because Frontier's AbbVie collaboration is also focused on E3 ligases, making Arvinas a peer in the same target class and partnership ecosystem.
- Foghorn Therapeutics: Clinical-stage precision oncology company developing medicines against previously undruggable targets in chromatin biology using its Gene Traffic Control platform. Comparable to Frontier in its platform-driven approach to historically difficult targets and clinical-stage development focus.
Emerging players
- Erasca: Clinical-stage precision oncology company focused on the RAS/MAPK pathway with multiple programs targeting KRAS and downstream nodes. Relevant peer in the oncology indication overlap, particularly for KRAS G12C and PI3K/RAS pathway programs where Frontier also competes.
- Insitro: AI-driven drug discovery company combining high-throughput biology, machine learning, and chemistry to discover new medicines. Adjacent peer to Frontier in AI-enabled discovery, though Insitro focuses on phenotypic data and broader modalities vs. Frontier's covalent chemistry specialization.
Broad incumbents
- Amgen (Lumakras/sotorasib program): Large biopharmaceutical company and first-to-market with Lumakras (sotorasib), a KRAS G12C inhibitor approved in NSCLC. Represents the incumbent benchmark Frontier's FMC-376 dual mechanism aims to differentiate against, though Amgen's broader portfolio means KRAS is one of many programs.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Frontier Medicines social profiles
Digital presenceFrontier Medicines financial estimates
Financial estimateRevenue estimate
Valuation estimate
Frontier Medicines leadership team
Management profileNumber of profiles
Profiles17 records
Frontier Medicines funding detail
Funding detailFunding overview
Funding rounds4 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Frontier Medicines M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Frontier Medicines
What does Frontier Medicines do?
Frontier Medicines is a clinical-stage biopharmaceutical company that develops small molecule covalent drugs against previously undruggable disease-causing protein targets, primarily in oncology. Its proprietary Frontier Platform combines chemoproteomics, covalent chemistry, and artificial intelligence to discover covalent binding sites, identify actionable ligands, and accelerate optimization to clinical candidates. The company has a pipeline of precision oncology drug candidates including FMC-376 (KRAS G12C), FMC-220 (p53 Y220C), and FMC-242 (PI3Kα-RAS).
Is Frontier Medicines a public or private company?
Frontier Medicines is a private company. It is classified as venture growth investor backed and is currently operating.
When was Frontier Medicines founded?
Frontier Medicines was founded in 2019. It employs 101 to 250 people.
Where is Frontier Medicines based?
Frontier Medicines is headquartered in San Francisco, United States, in the North America region.
How does Frontier Medicines make money?
Two revenue lines are on record. Partnership and licensing revenue is the primary driver. The others are drug development and commercialization.
Who are Frontier Medicines's main competitors?
Direct peers on record are Revolution Medicines, Mirati Therapeutics, Black Diamond Therapeutics, Recursion Pharmaceuticals, Schrödinger Inc., Arvinas and Foghorn Therapeutics. Emerging players are Erasca and Insitro. Amgen (Lumakras/sotorasib program) is listed as a broad incumbent.
Does Frontier Medicines have an API?
No public API is recorded for Frontier Medicines.
What industry is Frontier Medicines in?
Frontier Medicines's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 5417 and its SIC code is 2834.